FDA Approves Casgevy to Treat Beta-Thalassemia
Casgevy is the first CRISPR-based medicine to be approved for use in the United States for sickle cell disease and beta-thalassemia.
Casgevy is the first CRISPR-based medicine to be approved for use in the United States for sickle cell disease and beta-thalassemia.
Although scientific progress in HSCT is ongoing, gaps remain in both access to care and outcomes. An Education Session will review the latest research on…
No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.
Wolters Kluwer (“we” or “us”) wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain…
David A. Braun, MD, PhD, highlights recent data focused on nivolumab plus cabozantinib in patients with non–clear cell renal cell carcinoma.
Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive…
Researchers sought to identify comorbidity patterns and their effect on outcomes for elderly patients with nasopharyngeal carcinoma.
Total national health expenditure is associated with geographical inequalities in lymphoid malignancy prognosis. Policy decisions on allocating economic resources and implementing evidence-based models of care…
Another study adds to research suggesting that assisted reproductive technology may increase the risk of leukemia in offspring.
The breadth and depth of disparities affecting LGBTQ+ people with cancer aren’t well known, but there’s growing research on the challenges this group faces.